Premium
Propranolol Treatment for Hemangioma of Infancy: Risks and Recommendations
Author(s) -
Lawley Leslie P.,
Siegfried Elaine,
Todd Jane L.
Publication year - 2009
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/j.1525-1470.2009.00975.x
Subject(s) - propranolol , medicine , infantile hemangioma , hemangioma , adverse effect , food and drug administration , drug administration , pediatrics , intensive care medicine , drug , anesthesia , surgery , pharmacology
Hemangioma of infancy is a condition that may be associated with significant morbidity. While evidence most supports the use of corticosteroids, there is no well‐defined or Federal Drug Administration (FDA)‐approved systemic therapy for hemangioma of infancy. All currently used treatments have significant risks. Dramatic improvement of complicated hemangioma of infancy to propranolol was recently reported, but details for initiating therapy, monitoring, and potential risks were not included. We present two infants treated with propranolol, who suffered complications and propose a treatment protocol to minimize potential adverse events.